Ozmosi | Torcetrapib Drug Profile

Product Description

Mechanisms of Action: CETP Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Latest Trial Update Date	Data Updated
NCT00134264	ILLUMINATE	P3	Terminated	Coronary Artery Disease	2007-06-01	2019-03-21	Treatments
2004-000156-16	2004-000156-16	P3	Terminated	Coronary Disease	2006-12-02	2025-07-03	Treatments
NCT00267280	A5091031	P3	Terminated	Dyslipidemia\|Hyperlipoproteinemias\|Hyperlipidemia\|Hypercholesterolemia	2006-12-01	2019-03-21	Treatments
NCT00145431	A5091024	P3	Terminated	Hyperlipoproteinemia Type III\|Hyperlipidemia\|Hyperlipoproteinemias	2006-12-01	2019-03-21	Treatments
NCT00138762	Fredrickson Types IIa and IIb	P3	Completed	Hyperlipoproteinemias\|Hyperlipidemia	2006-08-01	2019-03-21
2004-000139-27	2004-000139-27	P3	Completed	Dyslipidemia	2006-07-31	2022-03-12	Treatments
2004-004269-14	2004-004269-14	P3	Completed	Hypercholesterolemia	2006-02-21	2022-03-12	Treatments
NCT00137462	A5091019	P3	Completed	Hyperlipidemia\|Hyperlipoproteinemias	None	2019-03-21	Treatments
NCT00139061	A5091034	P3	Completed	Hyperlipidemia\|Hyperlipoproteinemias	None	2019-03-21	Treatments
NCT00134485	A5091026	P3	Completed	Hyperlipidemia\|Hyperlipoproteinemias\|Hypercholesterolemia\|Hyperlipoproteinemia Type II	None	2019-03-21	Treatments
NCT00267254	A5091030	P3	Completed	Hypercholesterolemia\|Dyslipidemia\|Hyperlipoproteinemias\|Hyperlipidemia	None	2019-03-21	Treatments
NCT00134498	A5091025	P3	Completed	Hyperlipidemia\|Hyperlipoproteinemia Type IV\|Hypertriglyceridemia\|Hyperlipoproteinemias	None	2019-03-21	Treatments
NCT00134511	A5091027	P3	Completed	Hyperlipoproteinemia Type II\|Hypercholesterolemia	None	2019-03-21	Treatments
NCT00267267	A5091035	P3	Terminated	Dyslipidemia\|Hyperlipidemia	None	2025-08-27	Primary Endpoints

Recent News Events

Date	Type	Title
01/01/2024	PubMed	Using TransR to enhance drug repurposing knowledge graph for COVID-19 and its complications.
04/01/2023	PubMed	Structure-based mechanism and inhibition of cholesteryl ester transfer protein.
02/01/2022	PubMed	Pharmacological Inhibition of CETP (Cholesteryl Ester Transfer Protein) Increases HDL (High-Density Lipoprotein) That Contains ApoC3 and Other HDL Subspecies Associated With Higher Risk of Coronary Heart Disease.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

Torcetrapib

Alternative Names: torcetrapib Clinical Status: Inactive Latest Update: 2024-01-01 Latest Update Note: PubMed Publication